ÿþ<HTML><HEAD><TITLE>XI International Meeting on Paracoccidioidomycosis</TITLE><link rel=STYLESHEET type=text/css href=css.css></HEAD><BODY aLink=#ff0000 bgColor=#FFFFFF leftMargin=0 link=#000000 text=#000000 topMargin=0 vLink=#000000 marginheight=0 marginwidth=0><table align=center width=700 cellpadding=0 cellspacing=0><tr><td align=left bgcolor=#cccccc valign=top width=550><font face=arial size=2><strong><font face=Verdana, Arial, Helvetica, sans-serif size=3><font size=1>XI International Meeting on Paracoccidioidomycosis</font></font></strong><font face=Verdana size=1><b><br></b></font><font face=Verdana, Arial,Helvetica, sans-serif size=1><strong> </strong></font></font></td><td align=right bgcolor=#cccccc valign=top width=150><font face=arial size=2><strong><font face=Verdana, Arial, Helvetica, sans-serif size=1><font size=1>Resume:44-1</font></em></font></strong></font></td></tr><tr><td colspan=2><br><br><table align=center width=700><tr><td><b>Poster (Painel)</b><br><table width="100%"><tr><td width="60">44-1</td><td><b>Evaluation of renal and liver blood chemistry before and in the follow-up of paracoccidioidomycosis-patients treated with cotrimoxazole or itraconazole.</b></td></tr><tr><td valign=top>Authors:</td><td><u>Adriele Dandara Levorato </u> (FMB - UNESP - Faculdade de Medicina de Botucatu) ; Daniela Vanessa Moris (FMB - UNESP - Faculdade de Medicina de Botucatu) ; Tatiane Fernanda Sylvestre (FMB - UNESP - Faculdade de Medicina de Botucatu) ; Ricardo de Souza Cavalcante (FMB - UNESP - Faculdade de Medicina de Botucatu) ; Lídia Raquel Carvalho (IBB - UNESP - Instituto de Biociência) ; Rinaldo Poncio Mendes (FMB - UNESP - Faculdade de Medicina de Botucatu) </td></tr></table><p align=justify><b><font size=2>Abstract</font></b><p align=justify class=tres><font size=2><b>Introduction.</b> Patients infected by <i>Paracoccidioides brasiliensis</i>, an eukaryote organism, are treated with itraconazole (ITC) or cotrimoxazole-CMX. Adverse effects on kidneys and liver should be evaluated during therapy and were the aims of this study. <b>Patients and Methods.</b> Forty-seven patients with confirmed paracoccidioidomycosis were studied, eight with the acute/subacute form-AF and 39 with the chronic form-CF. Eight cases were treated with ITC and 39 with CMX. Aminotransferases-ALT and AST, alkaline phosphatase-AP, &gamma- glutamil transferase-&gammaGT, total bilirrubin-TB, direct bilirrubin-DB, urea nitrogen-UN, creatinine, sodium, and potassium serum levels were evaluated at the Hospital Laboratory. PCM-p were evaluated at different moments: M1-before treatment; moments 2 (M2), 3 (M3) and 4 (M4): 4-6 weeks, 7-10 and 11-14 weeks after the beginning of the treatment. Comparison of groups was carried out by analysis of variance; to compare clinical forms at different periods or clinical forms and antifungal compounds the profile analysis of variance was used. Significance was set at p&le0.05. <b>Results.</b> 1. Pre-treatment (M1): 1a) TB levels showed CF>AF (p=0.001), although both averages were normal; 1b) AP levels were increase AF&geCF (p= 0.07); 1c) ALT (TGP) levels revealed CF>AF (p=0.04), within the normal range. 2. Effects of the therapy: 2a) at M2 potassium levels showed CF>AF (p=0.04), within the normal range; 2b) AP tended to normalize in the AF during the treatment (p=0.07); 2c) &gammaGT levels decreased after treatment (p=0.04) in the AF; 3. Comparisons between groups as to antifungal compound: 3a) potassium levels were higher in patients CMX-treated at M3 (p=0.01); 3b) TB levels showed ITC&geCMX (p=0.06) at M3; 3c) DB (p=0.005), at M2 and BUN (p=0.04), at M1 levels were higher in ITC-patients. <b>Conclusions.</b> Changes in renal and liver blood chemistry were observed and may be important markers for the prognosis and therapeutic follow-up of PCM cases. Clinical forms showed small differences as to antifungal side effects. Altered renal function and mild ITC-induced hepatotoxicity were few times observed, confirming the safety of these antifungal compounds.</font></p><br><b>Keyword: </b>&nbsp;Adverse effects, Cotrimoxazole, Itraconazole, Paracoccidioides brasiliensis, Paracoccidioidomycosis</td></tr></table></tr></td></table></body></html>